How effective are Wegovy tablets?
Wegovy tablets have been studied in a large Phase 3 clinical programme (the OASIS trials) involving adults living with overweight or obesity. In these studies, people received lifestyle advice alongside treatment to reflect real‑world use.

One key study, OASIS 4, followed adults with obesity or overweight and at least one weight‑related health problem for 64 weeks. Participants were randomly assigned to either oral semaglutide (Wegovy tablets) or placebo, in addition to lifestyle measures.

Average weight loss
In OASIS 4, people taking oral semaglutide 25 mg lost on average about 13.6% of their starting body weight, compared with around 2.2% in those taking placebo. When the analysis focused on participants who stayed fully on treatment for the full study period, mean weight loss rose to roughly 16.6% of their original body weight.

Clinically meaningful results
The trial also showed that many patients achieved substantial, clinically important weight loss.

Around three‑quarters of people lost at least 5% of their body weight
A significant proportion achieved losses of 10%, 15% and even 20% or more
In later analyses presented in 2026, almost one in three early responders went on to lose over 20% of their starting weight by week 64

How do Wegovy tablets compare with Wegovy injections?
Many patients want to know whether the tablet is as effective as the injection. The once‑weekly Wegovy injection is already recognised as one of the most effective weight‑management treatments available, with earlier studies of 2.4 mg showing average weight loss of about 15% of body weight and more recent 7.2 mg data reporting mean losses above 20%.

Early data suggest that the tablet formulation of semaglutide can deliver weight loss approaching that seen with the injection in many patients, especially when the medicine is taken consistently and alongside lifestyle changes. For many people, the main difference is likely to be convenience and personal preference rather than overall potential effectiveness.

How are Wegovy tablets taken?

Unlike the weekly injection, Wegovy tablets are taken once a day. To help the medicine absorb properly, patients are usually advised to:

• Take the tablet first thing in the morning
• Take it on an empty stomach
• Swallow it with a small amount of water
• Wait at least 30 minutes before eating, drinking or taking other medicines
• These instructions are important because semaglutide behaves differently when taken by mouth, and following them helps achieve more consistent levels of the drug in the bloodstream.

Possible side effects

The side‑effect profile of oral semaglutide is very similar to that of the injectable form. The most commonly reported effects are gastrointestinal and can include:

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Abdominal pain or discomfort
• Indigestion or heartburn
• For most patients these effects are mild to moderate and tend to improve as the body adapts to treatment. Slower dose increases and dietary adjustments can often help manage symptoms.

Who might benefit most from Wegovy tablets?

The tablet formulation may be particularly attractive for people who:

• Prefer oral medication over injections
• Feel anxious or uncomfortable about needles
• Travel frequently and want a simple daily routine
• Have postponed starting GLP‑1 treatment because of concerns about self‑injecting
• For these patients, having a tablet option may lower a key psychological barrier to starting evidence‑based weight‑management therapy.

The future of weight management

The introduction of Wegovy tablets marks an important step forward in obesity treatment. For the first time, some patients may be able to access a GLP‑1 medicine designed for weight management in tablet form, rather than relying solely on weekly injections.

In clinical studies, Wegovy tablets containing semaglutide have produced impressive weight‑loss outcomes, with average reductions of around 13.6% to 16.6% of starting body weight depending on adherence, and many individuals achieving considerably greater losses. While injectable Wegovy remains an excellent choice for many, the tablet formulation may open up GLP‑1 therapy to people who would otherwise avoid injections.

The most suitable option will always depend on your medical history, other medicines, lifestyle, and preferences. A consultation with a qualified healthcare professional is the best way to decide whether Wegovy tablets, Wegovy injections, or another approach is right for you.

Contact a member of the team if you didnt find the question you were looking for 02077607670. Or submit a private message here.

Times are given in working days and are approximate. Costs may change based on order total, day of the week or location within the UK. Ability to hit timescales will depend on whether the products are ordered before a cut off time, as well as additional administration time incurred in reviewing your order and courier schedules. 

Please review the estimates at the checkout.

Shipping Costs
Postage and packaging via Royal Mail £7.50

Please Note: These prices are shown as a guide only. All delivery times are approximate but have been obtained in good faith.
 
Discreet Delivery
All our items are sent completely discreet for your peace of mind.

This means the packaging is plain, there is no mention of what product is inside your package and there is no mention of Weight Medics either.

Returns Information
Customers can read our full returns policy by clicking here.